Key Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Histologically or cytologically documented locally advanced unresectable or metastatic
             non-squamous NSCLC that is not eligible for curative surgery and/or definitive
             chemoradiotherapy

          -  No prior systemic treatment for metastatic non-squamous NSCLC

          -  Known tumor programmed death-ligand 1 (PD-L1) status

          -  Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors,
             version 1.1 (RECIST v1.1)

          -  Life expectancy >= 12 weeks

          -  Adequate hematologic and end-organ function

          -  Negative human immunodeficiency virus (HIV) test at screening

          -  Serology test negative for active hepatitis B virus or active hepatitis C virus at
             screening.

        Key Exclusion Criteria:

          -  Mutations in epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma
             kinase (ALK) fusion oncogene

          -  Pulmonary lymphoepithelioma-like carcinoma subtype of NSCLC

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis

          -  History of malignancy other than NSCLC within 5 years prior to randomization, with the
             exception of malignancies with a negligible risk of metastasis or death

          -  Severe infection within 4 weeks prior to initiation of study treatment or any active
             infection that, in the opinion of the investigator, could impact patient safety

          -  Treatment with investigational therapy within 28 days prior to initiation of study
             treatment

          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including
             anti-cytotoxic T lymphocyte-associated protein 4, anti-TIGIT, anti-PD-1, and
             anti-PD-L1 therapeutic antibodies

          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination
             half-lives (whichever is longer) prior to initiation of study treatment

          -  Treatment with systemic immunosuppressive medication within 2 weeks prior to
             initiation of study treatment, or anticipation of need for systemic immunosuppressive
             medication during study treatment

          -  Known allergy or hypersensitivity or other contraindication to any component of the
             chemotherapy regimen the participant may receive during the study

          -  Women who are pregnant, or breastfeeding

          -  Known targetable c-ROS oncogene 1 (ROS1) or BRAFV600E genomic aberration.